ISU ABXIS Co Ltd (086890):製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:ISU ABXIS Co Ltd (086890) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C8056
◆発行会社(調査会社):GlobalData
◆発行日:2018年10月
◆ページ数:22
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:韓国
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
ISU ABXIS Co Ltd (ISU ABXIS), a subsidiary of ISU Chemical Co Ltd is a biotechnology company that discovers and develops diagnostic products and therapeutic antibodies. The company’s products include fabagal, abcertin, and clotinab. It offers clinical labs, in vitro diagnostics, chemotherapy response assay, genetic testing and tissue microarray programs, among others. ISU ABXIS also provides research and development programs for encompassing novel antigen screening, lead development and manufacturing process. The company’s antibodies are used for the treatment of heart diseases, mechanism disorders, enzyme treatment, cancer patients, autoimmune and inflammatory diseases, among others. ISU ABXIS is headquartered in Seongnam, South Korea.

ISU ABXIS Co Ltd (086890) – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ISU ABXIS Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deal Details 11
Partnerships 11
Isu Abxis Enters into Co-Development Agreement with Merck 11
PH&T Enters Into Commercialization Agreement With Isu Abxis For Zoledronic Acid 12
Licensing Agreements 13
Isu Abxis Amends its Licensing Agreement with Catalyst Biosciences for Factor IX Therapeutics 13
Equity Offering 15
ISU ABXIS Raises USD26 Million in Rights Offering of Shares 15
Isu Abxis Raises USD27.2 Million in Rights Offering of Shares 16
Isu Abxis Raises USD18 Million in Private Placement of Shares 17
Isu Abxis Raises USD14.4 Million in Private Placement of Shares 18
ISU ABXIS Co Ltd – Key Competitors 19
ISU ABXIS Co Ltd – Key Employees 20
ISU ABXIS Co Ltd – Locations And Subsidiaries 21
Head Office 21
Other Locations & Subsidiaries 21
Appendix 22
Methodology 22
About GlobalData 22
Contact Us 22
Disclaimer 22

List of Tables
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Key Facts, 2017 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISU ABXIS Co Ltd, Deals By Therapy Area, 2012 to YTD 2018 8
ISU ABXIS Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10
Isu Abxis Enters into Co-Development Agreement with Merck 11
PH&T Enters Into Commercialization Agreement With Isu Abxis For Zoledronic Acid 12
Isu Abxis Amends its Licensing Agreement with Catalyst Biosciences for Factor IX Therapeutics 13
ISU ABXIS Raises USD26 Million in Rights Offering of Shares 15
Isu Abxis Raises USD27.2 Million in Rights Offering of Shares 16
Isu Abxis Raises USD18 Million in Private Placement of Shares 17
Isu Abxis Raises USD14.4 Million in Private Placement of Shares 18
ISU ABXIS Co Ltd, Key Competitors 19
ISU ABXIS Co Ltd, Key Employees 20
ISU ABXIS Co Ltd, Other Locations 21
ISU ABXIS Co Ltd, Subsidiaries 21

List of Figures
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
ISU ABXIS Co Ltd, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
ISU ABXIS Co Ltd, Medical Devices Deals, 2012 to YTD 2018 9

★海外企業調査レポート[ISU ABXIS Co Ltd (086890):製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Genentech Inc-製薬・医療分野:企業M&A・提携分析
    Summary Genentech Inc (Genentech), a subsidiary of F. Hoffmann-La Roche Ltd, is a biotechnology company that develops and markets medicines to address serious medical needs. Its clinical development pipeline includes alectinib and Erlotinib for metastatic non-small cell lung cancer; Anti-ST2 for ast …
  • EKF Diagnostics Holdings Plc (EKF)-医療機器分野:企業M&A・提携分析
    Summary EKF Diagnostics Holdings Plc (EKF Diagnostics) is a medical device company which designs, develops, manufactures, and commercializes chemical reagents, and analyzers for the measurement of glucose, lactate, hematocrit, hemoglobin, and glycated hemoglobin. The company’s product portfolio comp …
  • EBSCO Industries Inc.:企業の戦略・SWOT・財務分析
    EBSCO Industries Inc. - Strategy, SWOT and Corporate Finance Report Summary EBSCO Industries Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • Royal College of Surgeons Ireland-製薬・医療分野:企業M&A・提携分析
    Summary Royal College of Surgeons Ireland (RCSI) is a not-for-profit organization that offers medical education and training in healthcare professions at undergraduate and postgraduate levels. The organization offers undergraduate courses in nursing, postgraduate research, postgraduate taught, leade …
  • Victorian WorkCover Authority:企業の戦略的SWOT分析
    Victorian WorkCover Authority - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major produ …
  • M3, Inc. (2413):企業の財務・戦略的SWOT分析
    M3, Inc. (2413) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the p …
  • FGL Sports Ltd. :企業の戦略・SWOT・財務情報
    FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report Summary FGL Sports Ltd. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • InviCRO LLC:製薬・医療:M&Aディール及び事業提携情報
    Summary InviCRO LLC (InviCRO) a subsidiary of Konica Minolta Inc, is a provider of image informatics, engineering and operational services in translational drug discovery and development. The company developed VivoQuant, a DICOM compliant post-processing suite for image data combining fundamental vi …
  • Coca-Cola HBC-Srbija d.o.o.:企業の戦略・SWOT・財務情報
    Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report Summary Coca-Cola HBC-Srbija d.o.o. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and ser …
  • Shanghai Desano Pharmaceutical Co Ltd:製薬・医療:M&Aディール及び事業提携情報
    Summary Shanghai Desano Pharmaceutical Co Ltd (Desano) is a drug manufacturing company that manufactures, develops, and markets generic APIs. The company’s products include generic APIs of anti-retroviral, oncology and anti-malarial products. It also provides APIs and FPPs. Desano's API manufacturin …
  • SPI Pharma Inc:企業の戦略的SWOT分析
    SPI Pharma Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and service …
  • Industrial and Commercial Bank of China Ltd:企業のM&A・事業提携・投資動向
    Industrial and Commercial Bank of China Ltd - Mergers & Acquisitions (M&A), Partnerships & Alliances and Investment Report Summary Marketline's Industrial and Commercial Bank of China Ltd Mergers & Acquisitions (M&A), Partnerships & Alliances and Investments report includes business description, det …
  • M.C. Dean, Inc.:戦略・SWOT・企業財務分析
    M.C. Dean, Inc. - Strategy, SWOT and Corporate Finance Report Summary M.C. Dean, Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corpo …
  • Monster Worldwide Inc:企業の戦略的SWOT分析
    Monster Worldwide Inc - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • GOBARTO S.A.:戦略・SWOT・企業財務分析
    GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report Summary GOBARTO S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate a …
  • Centerra Gold Inc.:企業の戦略・SWOT・財務情報
    Centerra Gold Inc. - Strategy, SWOT and Corporate Finance Report Summary Centerra Gold Inc. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Enel Green Power SpA:企業の戦略的SWOT分析
    Enel Green Power SpA - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and s …
  • DTE Energy Co (DTE):企業の財務・戦略的SWOT分析
    DTE Energy Co (DTE) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and t …
  • Kajima Corporation:企業の戦略・SWOT・財務情報
    Kajima Corporation - Strategy, SWOT and Corporate Finance Report Summary Kajima Corporation - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and …
  • Advanced BioScience Laboratories Inc-製薬・医療分野:企業M&A・提携分析
    Summary Advanced BioScience Laboratories Inc (ABL), a subsidiary of Institut Merieux SA is a contract research and manufacturing company that provides services to life sciences industry. The company develops vaccines, therapeutics and other biologic products. It provides proof-of-concept in vivo stu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆